Sun Pharmaceutical Industries has received approval from ANVISA, Brazil's national health regulatory agency, to market semaglutide injections for the treatment of Type 2 diabetes in Brazil. The company expects to launch the product within days through a partnership with Hypera Pharma, a major Brazilian pharmaceutical company.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood sugar control in adults with Type 2 diabetes. It works by stimulating insulin secretion and reducing glucagon release in a glucose-dependent manner. The drug is widely known globally under brand names including Ozempic, Rybelsus, and Wegovy, marketed by Novo Nordisk. Global demand for GLP-1 receptor agonists has surged in recent years, driven by their demonstrated efficacy in blood sugar management and weight reduction, leading to widespread supply constraints that have prompted regulators in multiple countries to monitor availability.

Sun Pharma, India's largest pharmaceutical company by market capitalization, has been expanding its global footprint across emerging markets. Brazil ranks among the largest pharmaceutical markets in Latin America and has a significant population living with Type 2 diabetes, making it a strategically important market for chronic disease therapies.

Hypera Pharma, formerly known as Hypermarcas, is one of Brazil's leading pharmaceutical companies with a broad portfolio spanning prescription drugs and consumer health products. The partnership leverages Hypera's established local distribution and commercial infrastructure to facilitate Sun Pharma's market entry.

The ANVISA approval represents a regulatory milestone for Sun Pharma's entry into Brazil's GLP-1 receptor agonist segment for diabetes management. Sun Pharma's move into this category in an emerging market reflects a broader industry trend of Indian pharmaceutical companies targeting complex, high-growth therapeutic segments beyond traditional small-molecule generics.

Source: CNBC-TV18